Oriental Rise Faces Nasdaq Delisting as Panel Denies Appeal; Company Seeks Reconsideration

What happened

Oriental Rise Holdings Ltd (ORIS) disclosed on June 24, 2026 that the Nasdaq Hearings Panel has decided to delist the company's ordinary shares from the Nasdaq Capital Market, and the company is requesting reconsideration. This follows a history of bid-price deficiency struggles, including a reverse stock split in December 2025 that temporarily regained compliance. The delisting decision escalates a persistent overhang that the master report identified as a thesis breaker—renewed Nasdaq deficiency risk that could drive the stock toward $0.80. The company now faces an uphill battle to reverse the panel's decision while dealing with weak operating fundamentals: revenue collapsed to $15M in 2024 from $24M, and gross margins halved on price compression. This event crystallizes the downside scenario in the master report, where compliance stress and lack of meaningful operational improvement converge.

Implication

Investors should exit or size down aggressively. The delisting decision, combined with the master report's bear case ($0.80 implied value) and the company's history of dilutive financing, signals heightened risk of capital impairment. Only if the company quickly reverses the ruling via reconsideration and simultaneously delivers a definitive acquisition agreement with clean funding, while showing pricing stabilization, would the thesis be salvageable.

Thesis delta

The thesis shifts from a 'WAIT' for cleaner financing and operational stability to a defensive posture: delisting risk is now a realized event, not a tail risk. The master report's bear case of $0.80 becomes the likely baseline if the reconsideration fails or further dilutive actions follow. Any remaining upside from M&A or margin recovery is contingent on first resolving the Nasdaq status, which management has limited control over.